Skip to main content

Developments in Pharmaceutical and Biotech Patent Law 2015

Author(s): Daniel L. Reisner, David K. Barr
Practice Area: Intellectual Property
Published: Oct 2015
PLI Item #: 136819
CHB Spine #: G1240

David K. Barr’s practice is concentrated in the areas of patent, trade secret, and unfair competition litigation and counseling. David’s experience includes litigation in federal and state courts, appeals to the Federal Circuit Court of Appeals and practice before the US Patent and Trademark Office. David has been lead trial counsel in many complex patent infringement cases, and has counseled clients on product development and strategic patent planning. He has extensive experience in intellectual property transactions, including licenses and acquisitions. David has conducted numerous patent due diligence investigations, and has drafted patent license and related agreements. His patent matters have involved a variety of technologies, including biotechnology, pharmaceuticals, industrial chemistry and biomedical and mechanical devices.

David was recently recognized as an “IP Star” by Managing IP Handbook 2015, and as a “life sciences hot shot” for his work in patent litigation by the IAM Patent 1000 2014 guide of The World’s Leading Patent Practitioners, adding that David is an “extremely diligent lawyer and fine strategist.” In the 2014 and 2015 editions of Euromoney's LMG Life Sciences Guide, David was named a "Life Science Star," and in 2016 was recognized by Who's Who Legal for patent litigation. He was also selected as a “2013 Top Rated Lawyer in Intellectual Property Law” by American Lawyer and Corporate Counsel Magazine. Furthermore, Kaye Scholer’s Patent Litigation Practice was rated as “highly recommended” by the ILA’s Leaders League in 2012, with David noted as a “leading partner” within the practice.

David has authored articles and has lectured on a variety of intellectual property issues. He is a co-author and co-editor of the treatise Pharmaceutical and Biotech Patent Law (Practising Law Institute, 2015).

Daniel Reisner's practice focuses on patent and trade secret litigation, intellectual property licensing, and general complex commercial disputes. His intellectual property experience includes biotechnology, pharmaceuticals, ANDA litigations, medical devices, telecommunications, computers, plastic injection molding manufacture and aerospace systems.

Daniel has worked on numerous trials, has broad experience in all phases of litigation. He has been identified as a “Future Star” by the publisher of Institutional Investor and in the 2014 edition of Benchmark Litigation, and is recommended by The Legal 500 United States 2013. Examples of matters on which Daniel has worked include representation of Pfizer Inc in a patent infringement suit brought by the University of Rochester involving Celebrex®, a multibillion-dollar drug for the treatment of arthritis. The case resulted in victory for Pfizer with a decision by the Federal Circuit upholding the district court’s decision invalidating the patent-in-suit on a motion for summary judgment. In a subsequent suit against a generic, Daniel represented Pfizer in obtaining a victory at trial and affirmance on appeal. Another example is Daniel’s representation of Chiron Corporation in multiple actions involving its hepatitis C virus patents resulting in numerous dismissals of the opposing parties’ claims and defenses. He has also negotiated and drafted numerous patent and technology licenses for clients such as Novartis Pharmaceuticals Corporation, Pfizer and others.

Daniel also represents clients in telecommunications- and computer-related patent disputes. The technologies involved aspects of broadband data and video transmission, coaxial cable and optical data transmission, headends, data centers, computer networking, satellite communication, NTSC, ATSC, MPEG and DOCSIS standards, videotex, handheld computing, memory, peripherals and microprocessors.

Daniel is the co-editor and a principal contributing author of Pharmaceutical and Biotech Patent Law, published by the Practising Law Institute, and frequently speaks and writes about a variety of patent and licensing issues.